<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>734884_111</messagenumb>
		<messagesenderidentifier>LILLYFDA</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151008</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>ZA-ELI_LILLY_AND_COMPANY-ZA201301002968</safetyreportid>
		<primarysourcecountry>ZA</primarysourcecountry>
		<occurcountry>ZA</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130121</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121211</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130116</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>ZA-ELI_LILLY_AND_COMPANY-ZA201301002968</companynumb>
		<primarysource>
			<reportercountry>ZA</reportercountry>
			<qualification>1</qualification>
		</primarysource>
		<primarysource>
			<reportercountry>ZA</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>Eli Lilly and Company</senderorganization>
			<senderdepartment>BS200</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>John</sendergivename>
			<sendermiddlename>A.</sendermiddlename>
			<senderfamilyname>Fredenburg</senderfamilyname>
			<senderstreetaddress>Lilly Corporate Center</senderstreetaddress>
			<sendercity>Indianapolis</sendercity>
			<senderstate>IN</senderstate>
			<senderpostcode>46285</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2770207</sendertel>
			<sendertelcountrycode>317</sendertelcountrycode>
			<senderfax>8666441697</senderfax>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>Food and Drug Administration - CDER</receiverorganization>
			<receiverdepartment>Office of Surveillance and Epidemiology</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20851</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3017709299</receivertel>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3017706614</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>RB</patientinitial>
			<patientsex>1</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Type 1 diabetes mellitus</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>hyperglycemia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hyperglycemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hyperglycaemia</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121206</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20121209</reactionenddate>
				<reactionduration>4</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>2</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testname>Blood glucose</testname>
				<testresult>&gt; 20</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>ZA</obtaindrugcountry>
				<drugbatchnumb>C012156H</drugbatchnumb>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugstructuredosagenumb>74</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>74 DF, qd</drugdosagetext>
				<drugdosageform>Injection</drugdosageform>
				<drugadministrationroute>058</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121205</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20121208</drugenddate>
				<drugtreatmentduration>4</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>6</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>ZA</obtaindrugcountry>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugdosagetext>UNK, unknown</drugdosagetext>
				<drugdosageform>Injection</drugdosageform>
				<actiondrug>6</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This spontaneous case, reported by a physician who contacted the company via a sales representative to report an adverse event, concerns a male patient of unknown age and ethnicity. Additional information was provided by the physician reporter.

The patient was a reasonably well controlled type I diabetic. Concomitant medications were not provided.

The patient received insulin lispro (Humalog) 74 units daily (reported as 74/26/24) via a disposable KwikPen device, beginning on 05-Dec-2012 for an unspecified indication. On 06-Dec-2012, the day after initiating insulin lispro, the patient experienced hyperglycemia with blood sugars of greater than 20 mmol/l (with no diabetic ketoacidosis) after using two insulin lispro Kwikpens of lot number C012156H. Subsequently, the patient was hospitalized for hyperglycemia on an unspecified date between 06-Dec-2012 and 08-Dec-2012.  At the time of the event, the patient did not have an infection, infarction, hypoglycemia and Somogyi effect, no increased stress levels and no problems with injection site. Initially, it was reported the patient experienced hypoglycemia. On 08-Dec-2012, insulin lispro was discontinued in the hospital and the hyperglycemia resolved on 09-Dec-2012. Upon follow-up, it was also stated the patients blood glucose only settled into normal values with a new prefilled pen was given to the patient and insulin lispro therapy was ongoing.  Further corrective treatments and additional information regarding hospitalization were not provided. Date of hospital discharge was unknown. 

The report contained a suspect insulin lispro prefilled disposable KwikPen device (lot number C012156H associated with product complaint 2465077). The operator of the device and the training status of the patient were not reported. General device duration of use and suspect device duration of use were reported as two days. At the time of follow-up, the device was being returned to the manufacturer for evaluation. 

The reporting physician related the event of hyperglycemia to insulin lispro and the disposable KwikPen device, as the patients blood glucose only settled into normal values after initiating a new Kwikpen.

Update 18-Jan-2013: Additional information was received on 16-Jan-2013 from the initial physician reporter. Reporter demographics were updated; medical history of type I diabetes added; blood glucose laboratory value was added; insulin lispro formulation updated to prefilled disposable Kwikpen; action taken with insulin lispro was updated to change to new pre-filled pen; suspect insulin lispro Kwikpen disposable device was added; event of hypoglycemia was updated to hyperglycemia; physician causality was changed to yes; expectedness was updated for the event of hyperglycemia and case narrative was updated to reflect additional information received.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
